Presentation is loading. Please wait.

Presentation is loading. Please wait.

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants:

Published byCzesław Orzechowski Modified over 6 years ago

Similar presentations

Presentation on theme: "Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants:"— Presentation transcript:

1 Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model by Rohit M. Oemrawsingh, K. Martijn Akkerhuis, Laura C. Van Vark, W. Ken Redekop, Goran Rudez, Willem J. Remme, Michel E. Bertrand, Kim M. Fox, Roberto Ferrari, A.H. Jan Danser, Moniek de Maat, Maarten L. Simoons, Jasper J. Brugts, Eric Boersma, and J Am Heart Assoc Volume 5(3):e002688 March 28, 2016 © 2016 Rohit M. Oemrawsingh et al.

2 Clinical risk score distribution.
Clinical risk score distribution. The mean value of the clininal risk score (N=8726) was of 7.67±2.83. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.

3 Absolute risks of the primary endpoint across different clinical (X‐axis) and pharmocogenetic risk strata (Panels A through D). Absolute risks of the primary endpoint across different clinical (X‐axis) and pharmocogenetic risk strata (Panels A through D). P values were derived from multivariate Cox proportional hazards regression models fitted with the following covariates: clinical risk score; PGXscore; treatment; and treatment×PGXscore interaction. PGXscore indicates pharmacogenetic risk score. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.

4 Absolute risk reduction (Y‐axis on a 0 to 1 scale) by perindopril across different levels of clinical (X‐axis) and pharmacogenetic risk. Absolute risk reduction (Y‐axis on a 0 to 1 scale) by perindopril across different levels of clinical (X‐axis) and pharmacogenetic risk. PGXscore indicates pharmacogenetic risk score. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.

5 Observed versus estimated risks according to the clinical and combined (full) risk prediction models. Observed versus estimated risks according to the clinical and combined (full) risk prediction models. P values were derived from Hosmer‐Lemeshow goodness‐of‐fit test. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.

Download ppt "Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants:"

Similar presentations

When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.

When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Challenges When Conducting Economic Evaluation Alongside Clinical Trials: Experience Of Economic Appraisal In Cardiovascular Disease Andrew Briggs University.

Challenges When Conducting Economic Evaluation Alongside Clinical Trials: Experience Of Economic Appraisal In Cardiovascular Disease Andrew Briggs University.
Model Checking in the Proportional Hazard model

Model Checking in the Proportional Hazard model
Cox Proportional Hazards Regression Model Mai Zhou Department of Statistics University of Kentucky.

Cox Proportional Hazards Regression Model Mai Zhou Department of Statistics University of Kentucky.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
R Ferrari, WJ Remme, M Simoons, M Bertrand, K FOX, On behalf of the EUROPA investigators. A sub study of PERTINENT PER indopril – T hrombosis, I nflammatio.

R Ferrari, WJ Remme, M Simoons, M Bertrand, K FOX, On behalf of the EUROPA investigators. A sub study of PERTINENT PER indopril – T hrombosis, I nflammatio.
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.

Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.

Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Impact of ACE inhibitors and Angiotensin II receptor blockers on all- cause mortality in hypertension trials Congress of the European Society of Cardiology.

Impact of ACE inhibitors and Angiotensin II receptor blockers on all- cause mortality in hypertension trials Congress of the European Society of Cardiology.
Lecture 12: Cox Proportional Hazards Model

Lecture 12: Cox Proportional Hazards Model
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349. ?

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Charlotte Kragelund et al N Engl J Med 2005;352:666- 75 Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,

Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,

Similar presentations

Ads by Google